Quick-Med grants Microfoam license for Central Asia

Viridis will have the right to sell the Microfoam dressings it produces under license from Quick-Med to territories now including the Commonwealth of Independent States (CIS). Countries within the expanded territory include Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, as well as Georgia, Turkmenistan and the Ukraine.

Distribution into these territories will be handled by Unique Pharmaceutical Labs, a company based in India, which has an extensive sales and commercial networks in the territories granted. The regulatory clearance process is already underway for Russia, with others following. This expanded contract has a term of 5 years. The core contract between Viridis and QMT that permits manufacture and sale in India of foam and gauze NIMBUS products is extended for the same period.

"We are extremely excited to continue the expansion of this unique technology further into emerging markets," said Bernd Liesenfeld, Quick-Med's president. "These emerging markets are seeing increasing investments in health care, and their fast growing wound care markets represent a significant opportunity for Viridis to provide patients and caregivers with a great product, and to drive sales with our unique, value-added NIMBUS antimicrobial feature.

"This technology can succeed in these markets because of its optimal combination of safety, efficacy and economical price that places it in reach of more patients and health providers."

As part of its commercialization efforts, Viridis BioPharma has sponsored clinical trials to demonstrate the efficacy of Microfoam dressings, the first of which are nearing initial reporting. "India tops the diabetes sufferers list as per World Health Organization (WHO) figures and consequently chronic diabetic wounds and ulcers.

Quick-Med's NIMBUS Technology applied through Microfoam dressing shows remarkable relief in burn and wound cases and particularly in diabetic chronic wounds, as well as in venous and pressure ulcers, in an Indian clinical trial," commented Dr. Dilip Mehta, CEO of Viridis BioPharma Pvt. Ltd.

"The Microfoam dressing offers an opportunity to help prevent bacterial infections, with affordable products, that are accessible to a much wider patient base than competing products, many of which are based on silver. Initial clinical observations on Microfoam cite that wounds show faster healing with Microfoam than with conventional treatments."

Quick-Med